Evidence map›Paper›PMID 32111818›Full record

ArticleCell death & disease2020

Pharmacological LRH-1/Nr5a2 inhibition limits pro-inflammatory cytokine production in macrophages and associated experimental hepatitis.

Juliane Schwaderer, Truong San Phan, Astrid Glöckner, Johannes Delp, Marcel Leist, Thomas Brunner, M Eugenia Delgado

Abstract read
In one paragraph

Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Frontiers in immunology · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Juliane SchwadererBiochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany.
Truong San PhanBiochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany.ORCID http://orcid.org/0000-0002-8837-5119
Astrid GlöcknerBiochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany.
Johannes DelpIn Vitro Toxicology and Biomedicine, inaugurated by the Doerenkamp-Zbinden Foundation, Department of Biology, University of Konstanz, Konstanz, Germany.ORCID http://orcid.org/0000-0003-3224-0677
Marcel LeistIn Vitro Toxicology and Biomedicine, inaugurated by the Doerenkamp-Zbinden Foundation, Department of Biology, University of Konstanz, Konstanz, Germany.ORCID http://orcid.org/0000-0002-3778-8693
Thomas Brunner *Biochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany.
M Eugenia Delgado *Biochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany. eugenia.delgado@uni-konstanz.de.ORCID http://orcid.org/0000-0002-8653-1819

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver receptor homolog-1 (LRH-1, Nr5a2) is an orphan nuclear receptor mainly expressed in tissues of endodermal origin, where its physiological role has been extensively studied. LRH-1 has been implicated in liver cell differentiation and proliferation, as well as glucose, lipid, and bile acid metabolism. In addition, increasing evidence highlights its role in immunoregulatory processes via glucocorticoid synthesis in the intestinal epithelium. Although the direct function of LRH-1 in immune cells is fairly elucidated, a role of LRH-1 in the regulation of macrophage differentiation has been recently reported. In this study, we aimed to investigate the role of LRH-1 in the regulation of pro-inflammatory cytokine production in macrophages. Our data demonstrate that pharmacological inhibition, along with LRH-1 knockdown, significantly reduced the lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines in the macrophage line RAW 264.7 cells, as well as in primary murine macrophages. This inhibitory effect was found to be independent of defects of LRH-1-regulated cell proliferation or toxic effects of the LRH-1 inhibitors. In contrast, LRH-1 inhibition reduced the mitochondrial ATP production and metabolism of macrophages through downregulation of the LRH-1 targets glucokinase and glutminase-2, and thus impairing the LPS-induced macrophage activation. Interestingly, in vivo pharmacological inhibition of LRH-1 also resulted in reduced tumor necrosis factor (TNF) production and associated decreased liver damage in a macrophage- and TNF-dependent mouse model of hepatitis. Noteworthy, despite hepatocytes expressing high levels of LRH-1, pharmacological inhibition of LRH-1 per se did not cause any obvious liver damage. Therefore, this study proposes LRH-1 as an emerging therapeutic target in the treatment of inflammatory disorders, especially where macrophages and cytokines critically decide the extent of inflammation.

Indexed as

AnimalsCell DifferentiationCell ProliferationCytokinesGene ExpressionHepatitisHepatocytesIntestinal MucosaLiver DiseasesMacrophagesMiceReceptors, Cytoplasmic and NuclearCytokinesNr5a2 protein, mouseReceptors, Cytoplasmic and Nuclear

Identifiers

PMID32111818
PMCPMC7048823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.